Overview of the drug development pipeline for hyperphosphatemia
It has been observed that hyperphosphatemia is a condition characterized by an electrolyte imbalance, which results in a high level of serum phosphate concentration greater than 1.46 mmol/L in the blood. Hyperphosphatemia is common among people suffering from chronic kidney disease, especially the people with end-stage kidney disease. One of the main function of the kidney is processing and excreting waste through urine. When patients are affected with chronic kidney disease, the kidney fails to excrete compounds such as phosphate, which starts to build up in the bloodstream and after it reaches a high level, it causes hyperphosphatemia. Monotherapy is emerging as the most efficient approach for the treatment of hyperphosphatemia.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for hyperphosphatemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Drug development pipeline report for hyperphosphatemia: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperphosphatemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- 3SBio
- Ardelyx
- Chugai Pharmaceuticals
Therapeutic assessment of the drug development pipeline for hyperphosphatemia by route of administration
- Oral
The oral route of administration (ROA) involves the placement of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for hyperphosphatemia by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for hyperphosphatemia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for hyperphosphatemia?
- What are the companies that are currently involved in the development of drug molecules for hyperphosphatemia?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.